Salix finally submits crofelemer NDA, but Napo disputes authority after deal end
This article was originally published in Scrip
Salix Pharmaceuticals held to its word to deliver a new drug application (NDA) to the US FDA for crofelemer as a treatment for HIV-associated diarrhea, but Napo Pharmaceuticals, which terminated its deal with the company, is arguing that its former partner does not have the legal authority to submit or pursue the NDA.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.